Multiple myeloma is the second most common blood cancer in the United States, and it is more common in men, with an estimated ...
TOKYO -- The leader of Japanese opposition party Reiwa Shinsengumi, Taro Yamamoto, 51, announced on the party's YouTube ...
Men are twice as likely as women to have stage III multiple myeloma at diagnosis and appear to have a greater tumor burden than women, according to ...
The mother and daughter received identical diagnoses just over a year apart of multiple myeloma, a blood cancer that occurs ...
ABC 11 Raleigh, NC on MSN
Five-year cancer survival rates hit 70% as doctors credit screening, treatment advances
Many of these advances and breakthroughs are the result of decades of work and clinical trials.
The FDA released a draft guidance document that provides a regulatory framework for sponsors to utilize minimal residual ...
In an interview with Targeted Oncology, George Mulligan, PhD, discussed the key takeaways from analysis of the Immune Atlas ...
In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change ...
Tecvayli and Darzalex combination shows unprecedented progression-free survival in relapsed/refractory multiple myeloma, ...
Overall, MajesTEC-3 signals a meaningful step forward for combination bispecific therapies in multiple myeloma, while ...
After a short delay and concerns of potential intervention from senior officials, the FDA has issued a draft guidance for the industry on the potential use of minimal residual disease (MRD) and ...
Data shows iberdomide combination therapy delivers progression free survival and safety in relapsed and refractory multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback